Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency
HemaSphere · 2025-08 · 9 (8)
DOI: 10.1002/hem3.70197 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 18.08.2025. Verfasst von Chenggong Tu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Research Center, Team Hematology and Immunology Vrije Universiteit Brussel Brussels Belgium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) remains incurable due to the development of drug resistance. We previously showed that communication between bone marrow stromal cells (BMSCs) and MM cells supports MM growth and triggers therapy resistance. This communication occurs through a plethora of mechanisms, including the release of cytokines and small extracellular vesicles (sEVs). The PDZ protein syntenin is a master regulator of intercellular communication, in particular via sEVs. In this study, we aimed to explore whether targeting syntenin, by genetic alteration or pharmacological inhibition, can disrupt BMSC–MM crosstalk, thereby rendering the MM cells more sensitive to therapy. We found that syntenin (SDCBP) is highly expressed in inflammatory BMSC of MM patients and that its expression in BM aspirates correlates with poor patient survival. Using in vitro models, we established that knockout of syntenin in BMSC alters their secretome and abolishes BMSC‐induced bortezomib resistance of MM cells via regulation of STAT3, MAPK, and AKT‐mTOR pathways. Pharmacological inhibition of syntenin decreases syntenin and IL‐6 sorting into BMSC sEVs and enhances bortezomib‐induced MM cell death. Finally, we validated the therapeutic added value of syntenin inhibition in combination with bortezomib in vivo, using the 5TGM1 MM mouse model. In conclusion, our findings show that syntenin supports the secretion of pro‐tumoral factors by BMSCs and qualifies as a possible novel therapeutic target in MM.
Autor:innen und Institutionen
- Translational Oncology Research Center, Team Hematology and Immunology Vrije Universiteit Brussel Brussels Belgium.
- Laboratory for Extracellular Vesicle Research, Department of Human Genetics KULeuven Leuven Belgium.
- Equipe labellisée Ligue 2018, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, Inserm, CNRS, Institut Paoli-Calmettes Marseille France.
- Department of Hematology Erasmus MC Cancer Institute Rotterdam Rotterdam the Netherlands.
- Proteomics and Mass Spectrometry Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, Inserm, CNRS, Institut Paoli-Calmettes Marseille France.
ORCID-Profile: Tom Cupedo, Eline Menu
Zitieren
APA
Tu, C., Leblanc, R., Van der Vreken, A., Koops, M., Audebert, S., Goullieux, L., Meeussen, S., De Veirman, K., De Bruyne, E., Vanderkerken, K., David, G., Cupedo, T., Zimmermann, P., & Menu, E. (2025). Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency. HemaSphere, 9(8). https://doi.org/10.1002/hem3.70197
Vancouver
Tu C, Leblanc R, Van der Vreken A, Koops M, Audebert S, Goullieux L, et al. Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency. HemaSphere. 2025;9(8). doi:10.1002/hem3.70197
BibTeX
@article{Tu2025,
author = {Tu, Chenggong and Leblanc, Raphael and Van der Vreken, Arne and Koops, Marnix and Audebert, Stephane and Goullieux, Lauriane and Meeussen, Sofie and De Veirman, Kim and De Bruyne, Elke and Vanderkerken, Karin and David, Guido and Cupedo, Tom and Zimmermann, Pascale and Menu, Eline},
title = {Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {8},
doi = {10.1002/hem3.70197}
}
EUVIMED